Share Price and Basic Stock Data
Last Updated: February 3, 2026, 2:14 am
| PEG Ratio | 14.24 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Glenmark Pharmaceuticals Ltd operates within the pharmaceuticals sector, focusing on the development and commercialization of branded and generic medications. As of the latest reporting period, the company recorded a market capitalization of ₹54,212 Cr, with its stock priced at ₹1,920. Glenmark’s revenue from operations was ₹15,955 Cr on a trailing twelve-month (TTM) basis, reflecting a notable growth trajectory. Quarterly sales figures exhibited fluctuations, with a peak of ₹3,434 Cr in September 2024, while the most recent quarter reported sales of ₹3,207 Cr in September 2023. This indicates a continuous upward trend in revenue, particularly in the latter half of fiscal 2025. The company’s sales for the financial year ending March 2025 were reported at ₹13,322 Cr, a rise from ₹12,990 Cr in March 2023, showcasing a robust year-on-year growth. Overall, Glenmark’s business performance indicates a strong positioning within the competitive pharmaceutical market, aided by a diversified product portfolio and strategic market initiatives.
Profitability and Efficiency Metrics
Glenmark Pharmaceuticals reported a net profit of ₹1,010 Cr for the TTM, with a net profit margin of 7.86%, demonstrating its ability to convert revenue into profit effectively. The operating profit margin (OPM) stood at 18.50% for March 2025, indicating a consistent efficiency in managing operational costs relative to its sales. However, the company faced challenges in earlier quarters, particularly with an OPM of just 10% in March 2024, reflecting a dip in profitability. The interest coverage ratio (ICR) was reported at 11.90x, suggesting that the company has a strong capacity to meet its interest obligations. The return on equity (ROE) was recorded at 15.8%, which is relatively competitive within the sector, indicating effective use of shareholder funds. Glenmark’s cash conversion cycle (CCC) of 129 days reflects moderate efficiency in converting investments into cash flow, positioning the company favorably compared to industry benchmarks.
Balance Sheet Strength and Financial Ratios
The balance sheet of Glenmark Pharmaceuticals demonstrates a sound financial structure, with total assets amounting to ₹19,002 Cr as of September 2025, against total liabilities of ₹15,991 Cr. The company’s borrowings stood at ₹1,224 Cr, indicating a low leverage level with a debt-to-equity ratio of 0.24, which is significantly lower than the typical industry range, suggesting prudent financial management. Reserves have increased to ₹9,554 Cr, providing a cushion for future investments and operational stability. The price-to-book value (P/BV) ratio was reported at 4.91x, indicating a premium valuation relative to its book value, which can be attributed to market confidence in Glenmark’s growth potential. Furthermore, the current ratio of 1.56x indicates good short-term financial health, allowing the company to comfortably cover its short-term liabilities. Overall, Glenmark’s balance sheet reflects solid fundamentals, providing a stable foundation for future growth.
Shareholding Pattern and Investor Confidence
Glenmark Pharmaceuticals’ shareholding pattern reveals a balanced distribution among various stakeholders, with promoters holding 46.64% of the company. Foreign institutional investors (FIIs) accounted for 20.73%, while domestic institutional investors (DIIs) held 18.61%. This diversified ownership structure indicates a healthy level of investor confidence. The number of shareholders has shown a slight decline, from 3,00,106 in December 2022 to 1,98,789 in September 2025, signaling a potential consolidation among investors. Notably, FIIs experienced fluctuations in their stake, reducing from 23.19% in December 2022 to the current 20.73%, which may reflect market sentiment or strategic realignments. The presence of institutional investors typically enhances corporate governance and strategic direction, contributing positively to Glenmark’s operational ethos. Overall, the shareholding pattern suggests a robust framework of investor support, although the declining number of shareholders may warrant scrutiny.
Outlook, Risks, and Final Insight
Glenmark Pharmaceuticals is well-positioned for continued growth, bolstered by its strong revenue trends and solid profitability metrics. However, potential risks include fluctuations in global pharmaceutical regulations and the competitive landscape, which could impact market share and profitability. The company’s reliance on international markets may expose it to currency risks and geopolitical uncertainties. Additionally, the volatility in quarterly earnings, particularly the significant dip in net profit in March 2024, raises concerns about operational consistency. Conversely, strengths such as a robust balance sheet, prudent financial management, and a diversified product portfolio provide a buffer against market challenges. In scenarios where Glenmark can maintain its operational efficiency while expanding its market presence, it could significantly enhance its profitability. Conversely, if external pressures mount, the company may need to adapt its strategies to navigate potential downturns effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,473 Cr. | 319 | 479/192 | 71.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,464.08 Cr | 1,084.45 | 46.05 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,100 | 3,001 | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 |
| Expenses | 2,626 | 2,603 | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 |
| Operating Profit | 474 | 398 | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 |
| OPM % | 15% | 13% | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% | 22% |
| Other Income | 209 | -696 | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 |
| Interest | 97 | 109 | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 |
| Depreciation | 152 | 135 | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 |
| Profit before tax | 435 | -542 | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 |
| Tax % | 33% | -26% | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% | 24% |
| Net Profit | 291 | -403 | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 |
| EPS in Rs | 9.66 | -15.18 | 5.31 | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 |
Last Updated: February 5, 2026, 9:46 pm
Below is a detailed analysis of the quarterly data for Glenmark Pharmaceuticals Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 3,901.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,047.00 Cr. (Sep 2025) to 3,901.00 Cr., marking a decrease of 2,146.00 Cr..
- For Expenses, as of Dec 2025, the value is 3,031.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,687.00 Cr. (Sep 2025) to 3,031.00 Cr., marking a decrease of 656.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 870.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,360.00 Cr. (Sep 2025) to 870.00 Cr., marking a decrease of 1,490.00 Cr..
- For OPM %, as of Dec 2025, the value is 22.00%. The value appears to be declining and may need further review. It has decreased from 39.00% (Sep 2025) to 22.00%, marking a decrease of 17.00%.
- For Other Income, as of Dec 2025, the value is -140.00 Cr.. The value appears strong and on an upward trend. It has increased from -1,184.00 Cr. (Sep 2025) to -140.00 Cr., marking an increase of 1,044.00 Cr..
- For Interest, as of Dec 2025, the value is 41.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 66.00 Cr. (Sep 2025) to 41.00 Cr., marking a decrease of 25.00 Cr..
- For Depreciation, as of Dec 2025, the value is 154.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 141.00 Cr. (Sep 2025) to 154.00 Cr., marking an increase of 13.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 534.00 Cr.. The value appears to be declining and may need further review. It has decreased from 967.00 Cr. (Sep 2025) to 534.00 Cr., marking a decrease of 433.00 Cr..
- For Tax %, as of Dec 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 37.00% (Sep 2025) to 24.00%, marking a decrease of 13.00%.
- For Net Profit, as of Dec 2025, the value is 403.00 Cr.. The value appears to be declining and may need further review. It has decreased from 610.00 Cr. (Sep 2025) to 403.00 Cr., marking a decrease of 207.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 14.29. The value appears to be declining and may need further review. It has decreased from 21.63 (Sep 2025) to 14.29, marking a decrease of 7.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:20 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 13,322 | 15,955 |
| Expenses | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 10,712 | 10,618 | 10,970 | 11,854 |
| Operating Profit | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 2,278 | 1,195 | 2,351 | 4,101 |
| OPM % | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 18% | 10% | 18% | 26% |
| Other Income | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -449 | 336 | -259 | -1,811 |
| Interest | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 350 | 516 | 207 | 244 |
| Depreciation | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 611 | 582 | 486 | 519 |
| Profit before tax | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 868 | 434 | 1,399 | 1,527 |
| Tax % | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 57% | 430% | 25% | |
| Net Profit | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,010 |
| EPS in Rs | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 35.78 |
| Dividend Payout % | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.72% | 255.50% | 49.26% | -27.50% | 15.05% | -16.11% | 25.00% | 2.47% | -62.07% | -480.37% | 173.01% |
| Change in YoY Net Profit Growth (%) | 0.00% | 317.22% | -206.24% | -76.76% | 42.55% | -31.16% | 41.11% | -22.53% | -64.55% | -418.30% | 653.38% |
Glenmark Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | 159% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 33% |
| 3 Years: | 74% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 4:50 am
Balance Sheet
Last Updated: December 4, 2025, 1:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 2,956 | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 9,554 |
| Borrowings | 3,267 | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,627 | 1,231 | 2,473 | 1,224 |
| Other Liabilities | 2,176 | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,228 | 5,279 | 4,669 | 8,196 |
| Total Liabilities | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 14,358 | 15,991 | 19,002 |
| Fixed Assets | 3,091 | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 6,202 | 4,210 | 4,487 | 5,210 |
| CWIP | 5 | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,251 | 662 | 835 | 695 |
| Investments | 0 | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 |
| Other Assets | 5,331 | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 11,830 | 8,697 | 10,613 | 13,054 |
| Total Assets | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 14,358 | 15,991 | 19,002 |
Below is a detailed analysis of the balance sheet data for Glenmark Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 28.00 Cr..
- For Reserves, as of Sep 2025, the value is 9,554.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,821.00 Cr. (Mar 2025) to 9,554.00 Cr., marking an increase of 733.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,224.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,473.00 Cr. (Mar 2025) to 1,224.00 Cr., marking a decrease of 1,249.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8,196.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,669.00 Cr. (Mar 2025) to 8,196.00 Cr., marking an increase of 3,527.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 19,002.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15,991.00 Cr. (Mar 2025) to 19,002.00 Cr., marking an increase of 3,011.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 5,210.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,487.00 Cr. (Mar 2025) to 5,210.00 Cr., marking an increase of 723.00 Cr..
- For CWIP, as of Sep 2025, the value is 695.00 Cr.. The value appears to be declining and may need further review. It has decreased from 835.00 Cr. (Mar 2025) to 695.00 Cr., marking a decrease of 140.00 Cr..
- For Investments, as of Sep 2025, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 56.00 Cr. (Mar 2025) to 42.00 Cr., marking a decrease of 14.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,613.00 Cr. (Mar 2025) to 13,054.00 Cr., marking an increase of 2,441.00 Cr..
- For Total Assets, as of Sep 2025, the value is 19,002.00 Cr.. The value appears strong and on an upward trend. It has increased from 15,991.00 Cr. (Mar 2025) to 19,002.00 Cr., marking an increase of 3,011.00 Cr..
Notably, the Reserves (9,554.00 Cr.) exceed the Borrowings (1,224.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -2.00 | -2.00 | -2.00 | -3.00 | -3.00 | -3.00 | -2.00 | -1.00 | -2.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 |
| Inventory Days | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 |
| Days Payable | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 216 |
| Cash Conversion Cycle | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 129 |
| Working Capital Days | 62 | 47 | 51 | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 |
| ROCE % | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 12,636,078 | 2.78 | 2571.69 | N/A | N/A | N/A |
| Invesco India Midcap Fund | 1,864,031 | 3.68 | 379.37 | N/A | N/A | N/A |
| Invesco India Contra Fund | 1,850,088 | 1.82 | 376.53 | 1,662,235 | 2025-12-14 11:28:18 | 11.3% |
| Invesco India Large & Mid Cap Fund | 1,342,939 | 2.92 | 273.31 | N/A | N/A | N/A |
| HDFC Manufacturing Fund | 1,280,000 | 2.37 | 260.51 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 1,048,046 | 0.74 | 213.3 | N/A | N/A | N/A |
| Mahindra Manulife Multi Cap Fund | 989,000 | 3.28 | 201.28 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 952,877 | 1.02 | 193.93 | 463,185 | 2025-12-08 07:53:24 | 105.72% |
| Mirae Asset Healthcare Fund | 941,043 | 6.91 | 191.52 | 956,043 | 2025-12-15 03:13:43 | -1.57% |
| HDFC Balanced Advantage Fund | 885,046 | 0.17 | 180.12 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Cash EPS (Rs.) | 54.33 | -30.18 | 35.04 | 52.46 | 50.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Revenue From Operations / Share (Rs.) | 472.08 | 418.62 | 460.36 | 436.08 | 387.85 |
| PBDIT / Share (Rs.) | 87.36 | 72.13 | 91.97 | 88.14 | 75.65 |
| PBIT / Share (Rs.) | 70.13 | 51.50 | 70.31 | 70.89 | 59.93 |
| PBT / Share (Rs.) | 49.58 | 1.29 | 30.78 | 51.08 | 48.99 |
| Net Profit / Share (Rs.) | 37.11 | -50.80 | 13.37 | 35.21 | 34.38 |
| NP After MI And SOA / Share (Rs.) | 37.11 | -53.21 | 10.53 | 33.37 | 34.38 |
| PBDIT Margin (%) | 18.50 | 17.22 | 19.97 | 20.21 | 19.50 |
| PBIT Margin (%) | 14.85 | 12.30 | 15.27 | 16.25 | 15.45 |
| PBT Margin (%) | 10.50 | 0.30 | 6.68 | 11.71 | 12.63 |
| Net Profit Margin (%) | 7.86 | -12.13 | 2.90 | 8.07 | 8.86 |
| NP After MI And SOA Margin (%) | 7.86 | -12.71 | 2.28 | 7.65 | 8.86 |
| Return on Networth / Equity (%) | 11.83 | -19.13 | 3.13 | 10.36 | 13.73 |
| Return on Capital Employeed (%) | 19.62 | 17.01 | 13.84 | 16.13 | 14.83 |
| Return On Assets (%) | 6.52 | -10.45 | 1.53 | 5.51 | 6.21 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.40 | 0.28 | 0.55 |
| Total Debt / Equity (X) | 0.24 | 0.12 | 0.45 | 0.40 | 0.66 |
| Asset Turnover Ratio (%) | 0.87 | 0.70 | 0.71 | 0.42 | 0.42 |
| Current Ratio (X) | 1.56 | 1.28 | 1.96 | 1.77 | 1.75 |
| Quick Ratio (X) | 1.05 | 0.84 | 1.37 | 1.23 | 1.21 |
| Inventory Turnover Ratio (X) | 4.81 | 1.15 | 1.31 | 1.85 | 1.85 |
| Dividend Payout Ratio (NP) (%) | 6.73 | -4.69 | 23.73 | 7.49 | 7.27 |
| Dividend Payout Ratio (CP) (%) | 4.60 | -7.66 | 7.76 | 4.93 | 4.99 |
| Earning Retention Ratio (%) | 93.27 | 104.69 | 76.27 | 92.51 | 92.73 |
| Cash Earning Retention Ratio (%) | 95.40 | 107.66 | 92.24 | 95.07 | 95.01 |
| Interest Coverage Ratio (X) | 11.90 | 3.94 | 7.42 | 8.34 | 6.04 |
| Interest Coverage Ratio (Post Tax) (X) | 7.86 | -0.80 | 4.27 | 5.21 | 3.62 |
| Enterprise Value (Cr.) | 43947.27 | 26350.45 | 16364.27 | 15087.86 | 16656.12 |
| EV / Net Operating Revenue (X) | 3.30 | 2.23 | 1.26 | 1.23 | 1.52 |
| EV / EBITDA (X) | 17.83 | 12.95 | 6.31 | 6.07 | 7.80 |
| MarketCap / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| Retention Ratios (%) | 93.26 | 104.69 | 76.26 | 92.50 | 92.72 |
| Price / BV (X) | 4.91 | 3.44 | 1.38 | 1.37 | 1.86 |
| Price / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| EarningsYield | 0.02 | -0.05 | 0.02 | 0.07 | 0.07 |
After reviewing the key financial ratios for Glenmark Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.33. This value is within the healthy range. It has increased from -30.18 (Mar 24) to 54.33, marking an increase of 84.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 472.08. It has increased from 418.62 (Mar 24) to 472.08, marking an increase of 53.46.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 87.36. This value is within the healthy range. It has increased from 72.13 (Mar 24) to 87.36, marking an increase of 15.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 70.13. This value is within the healthy range. It has increased from 51.50 (Mar 24) to 70.13, marking an increase of 18.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 49.58. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 49.58, marking an increase of 48.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -50.80 (Mar 24) to 37.11, marking an increase of 87.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.21 (Mar 24) to 37.11, marking an increase of 90.32.
- For PBDIT Margin (%), as of Mar 25, the value is 18.50. This value is within the healthy range. It has increased from 17.22 (Mar 24) to 18.50, marking an increase of 1.28.
- For PBIT Margin (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 14.85, marking an increase of 2.55.
- For PBT Margin (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 10.50, marking an increase of 10.20.
- For Net Profit Margin (%), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -12.13 (Mar 24) to 7.86, marking an increase of 19.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 8. It has increased from -12.71 (Mar 24) to 7.86, marking an increase of 20.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.83. This value is below the healthy minimum of 15. It has increased from -19.13 (Mar 24) to 11.83, marking an increase of 30.96.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.62. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 19.62, marking an increase of 2.61.
- For Return On Assets (%), as of Mar 25, the value is 6.52. This value is within the healthy range. It has increased from -10.45 (Mar 24) to 6.52, marking an increase of 16.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.70 (Mar 24) to 0.87, marking an increase of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.28 (Mar 24) to 1.56, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has increased from 0.84 (Mar 24) to 1.05, marking an increase of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.81. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 4.81, marking an increase of 3.66.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.73. This value is below the healthy minimum of 20. It has increased from -4.69 (Mar 24) to 6.73, marking an increase of 11.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 20. It has increased from -7.66 (Mar 24) to 4.60, marking an increase of 12.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.27. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.27, marking a decrease of 11.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.40. This value exceeds the healthy maximum of 70. It has decreased from 107.66 (Mar 24) to 95.40, marking a decrease of 12.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.90. This value is within the healthy range. It has increased from 3.94 (Mar 24) to 11.90, marking an increase of 7.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -0.80 (Mar 24) to 7.86, marking an increase of 8.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 43,947.27. It has increased from 26,350.45 (Mar 24) to 43,947.27, marking an increase of 17,596.82.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 3. It has increased from 2.23 (Mar 24) to 3.30, marking an increase of 1.07.
- For EV / EBITDA (X), as of Mar 25, the value is 17.83. This value exceeds the healthy maximum of 15. It has increased from 12.95 (Mar 24) to 17.83, marking an increase of 4.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 93.26. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.26, marking a decrease of 11.43.
- For Price / BV (X), as of Mar 25, the value is 4.91. This value exceeds the healthy maximum of 3. It has increased from 3.44 (Mar 24) to 4.91, marking an increase of 1.47.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.02, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glenmark Pharmaceuticals Ltd:
- Net Profit Margin: 7.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.62% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.83% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20 (Industry average Stock P/E: 46.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/2, Mahalaxmi Chambers, Mumbai Maharashtra 400026 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Glenn Saldanha | Chairman & Managing Director |
| Mrs. Cherylann Pinto | Executive Director |
| Mr. Anurag Mantri | Executive Director & Global CFO |
| Mrs. B E Saldanha | Non Executive Director |
| Ms. Saira Ramasastry | Ind. Non-Executive Director |
| Mrs. Vijayalakshmi Iyer | Ind. Non-Executive Director |
| Mr. Pradeep Kumar Sinha | Ind. Non-Executive Director |
| Mr. Dipankar Bhattacharjee | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd's intrinsic value (as of 05 February 2026) is ₹872.73 which is 54.55% lower the current market price of ₹1,920.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹54,212 Cr. market cap, FY2025-2026 high/low of ₹2,286/1,275, reserves of ₹9,554 Cr, and liabilities of ₹19,002 Cr.
What is the Market Cap of Glenmark Pharmaceuticals Ltd?
The Market Cap of Glenmark Pharmaceuticals Ltd is 54,212 Cr..
What is the current Stock Price of Glenmark Pharmaceuticals Ltd as on 05 February 2026?
The current stock price of Glenmark Pharmaceuticals Ltd as on 05 February 2026 is ₹1,920.
What is the High / Low of Glenmark Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Glenmark Pharmaceuticals Ltd stocks is ₹2,286/1,275.
What is the Stock P/E of Glenmark Pharmaceuticals Ltd?
The Stock P/E of Glenmark Pharmaceuticals Ltd is 20.0.
What is the Book Value of Glenmark Pharmaceuticals Ltd?
The Book Value of Glenmark Pharmaceuticals Ltd is 340.
What is the Dividend Yield of Glenmark Pharmaceuticals Ltd?
The Dividend Yield of Glenmark Pharmaceuticals Ltd is 0.13 %.
What is the ROCE of Glenmark Pharmaceuticals Ltd?
The ROCE of Glenmark Pharmaceuticals Ltd is 19.4 %.
What is the ROE of Glenmark Pharmaceuticals Ltd?
The ROE of Glenmark Pharmaceuticals Ltd is 15.8 %.
What is the Face Value of Glenmark Pharmaceuticals Ltd?
The Face Value of Glenmark Pharmaceuticals Ltd is 1.00.